HCM
HUTCHMED (China) Limited NASDAQ$13.22
Mkt Cap $2.3B
52w Low $12.82
6.0% of range
52w High $19.50
50d MA $14.45
200d MA $15.14
P/E (TTM)
5.0x
EV/EBITDA
-55.9x
P/B
1.8x
Debt/Equity
0.1x
ROE
36.9%
P/FCF
-29.0x
RSI (14)
—
ATR (14)
—
Beta
0.45
50d MA
$14.45
200d MA
$15.14
Avg Volume
29.3K
About
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastri…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | AMC | 1.46 | 1.30 | -11.0% | 16.31 | -7.6% | -8.0% | -5.1% | -5.9% | -1.9% | -2.7% | — |
| Jul 2, 2025 | AMC | — | 1.30 | — | 15.69 | -0.8% | +0.8% | -1.7% | +1.5% | +3.9% | +1.8% | — |
| Mar 19, 2025 | AMC | -0.09 | 0.03 | +137.9% | 16.18 | +1.6% | -0.3% | -7.4% | -6.7% | -9.6% | -12.1% | — |
| Sep 30, 2024 | AMC | — | 0.03 | — | 19.53 | +0.8% | +2.4% | +6.6% | +2.2% | +7.6% | +7.3% | — |
| Jul 31, 2024 | AMC | — | 0.01 | — | 19.44 | -2.8% | -4.9% | -6.7% | -6.2% | +4.0% | +1.0% | — |
| Jun 10, 2024 | AMC | — | 0.07 | — | 18.08 | -0.9% | -0.9% | -0.9% | +3.1% | +0.2% | -1.1% | — |
| Feb 28, 2024 | AMC | -1.08 | -0.04 | +96.3% | 15.21 | +1.1% | -0.7% | -0.4% | -0.6% | -9.1% | -2.0% | — |
| Jul 31, 2023 | AMC | — | 0.10 | — | 14.07 | +5.2% | +7.9% | +0.8% | +12.4% | +17.1% | -1.4% | — |
| Jun 20, 2023 | AMC | — | 0.49 | — | 11.95 | -0.6% | -9.5% | -5.3% | -9.8% | -6.7% | -3.0% | — |
| Feb 28, 2023 | AMC | -1.02 | -0.12 | +88.5% | 16.55 | +4.8% | +3.6% | +4.8% | +5.3% | +2.7% | -0.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10 | BofA Securities | Maintains | Buy → Buy | — | $13.77 | $13.78 | +0.1% | +0.9% | +5.8% | +3.1% | +1.5% | +3.7% |
| Sep 22 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $17.04 | $16.69 | -2.1% | -2.2% | -6.2% | -6.8% | -7.3% | -8.2% |
| Jul 22 | BofA Securities | Maintains | Buy → Buy | — | $17.74 | $17.82 | +0.5% | -0.3% | -1.0% | +0.2% | -0.7% | +1.4% |
| Aug 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.44 | $18.90 | -2.8% | -4.9% | -6.7% | -6.2% | +4.0% | +1.0% |
| Nov 24 | Deutsche Bank | Upgrade | Hold → Buy | — | $18.24 | $19.21 | +5.3% | +5.5% | +4.7% | +6.1% | +3.0% | +5.7% |
| Nov 10 | Goldman Sachs | Maintains | Neutral → Neutral | — | $18.09 | $18.65 | +3.1% | +5.1% | +2.4% | +5.3% | +3.4% | -2.9% |
| Sep 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.38 | $15.15 | -1.5% | -3.4% | -7.0% | -9.8% | -8.8% | -2.8% |
| Jul 24 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.75 | $13.20 | +3.5% | +6.0% | +8.9% | +15.6% | +11.1% | +15.5% |
| Aug 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $13.93 | $13.90 | -0.2% | -1.9% | +1.5% | -0.5% | -0.5% | -0.3% |
| Aug 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.07 | $11.85 | -1.8% | -1.5% | +2.2% | +10.0% | +15.0% | +15.4% |
Data updated apr 26, 2026 10:47am
· Source: massive.com